Fida Biosystems

Executive Summary

Fida Biosystems is a Danish biotechnology company founded in 2016 that has developed a novel analytical platform based on Flow Induced Dispersion Analysis (FIDA). This technology enables label-free or labeled, in-solution quantification and characterization of molecular interactions using only nanoliters of sample. The platform addresses critical needs in biopharma R&D, including binding affinity measurements, quality control, and the characterization of challenging targets such as membrane proteins and intrinsically disordered proteins. By providing high-throughput, low-volume analysis without the need for surface immobilization or specialized labels, FIDA offers a compelling alternative to traditional techniques like SPR and ITC. The company targets the rapidly growing proteomics and diagnostics markets, with applications spanning drug discovery, biologics development, and biomarker validation. With a strong intellectual property position and an established commercial presence in Europe, Fida is well-positioned to capture market share as demand for advanced analytical tools increases.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation FIDA instrument with enhanced throughput70% success
• Q4 2026Strategic partnership with a top-20 pharmaceutical company for label-free binding assays50% success
• Q2 2026Series B funding round to support U.S. commercial expansion60% success